Parkwood LLC Increases Stock Position in Sanofi (NASDAQ:SNY)

Parkwood LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 15.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 255,717 shares of the company's stock after acquiring an additional 33,394 shares during the quarter. Sanofi comprises approximately 1.4% of Parkwood LLC's portfolio, making the stock its 17th largest holding. Parkwood LLC's holdings in Sanofi were worth $12,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new position in Sanofi during the 4th quarter worth $25,000. McClarren Financial Advisors Inc. grew its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Sanofi during the 4th quarter worth $31,000. Bessemer Group Inc. grew its position in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new position in Sanofi during the 4th quarter worth $44,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on SNY. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi has an average rating of "Buy" and a consensus price target of $63.33.

Sanofi Price Performance

SNY stock traded up $0.36 during trading on Monday, reaching $52.04. 697,819 shares of the company were exchanged, compared to its average volume of 2,374,326. The company has a market cap of $131.47 billion, a P/E ratio of 20.89, a PEG ratio of 1.01 and a beta of 0.55. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The stock's 50 day moving average price is $53.36 and its 200 day moving average price is $51.88. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm's revenue was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.78 earnings per share. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be given a $2.0369 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.